Vyleesi Cost in New York 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Is the Cash Price of Vyleesi in New York in 2026?

The cash price for brand-name Vyleesi at New York retail pharmacies sits at the manufacturer's list price of $1,200 per month in 2026. That figure covers four auto-injector pens (1.75 mg each), because the approved maximum is one injection per 24-hour period, with no more than one use per 24 hours and eight doses per month as a practical ceiling recommended in the prescribing information. [1]

Paying the full $1,200 out-of-pocket is uncommon for patients who do even minimal homework. Coupon aggregators such as GoodRx and RxSaver negotiate discounted rates with specific pharmacy chains, and the actual dispensed cash price at a New York Duane Reade, Walgreens, or Costco varies by 10 to 25 percent depending on the chain and the coupon applied. Calling at least three pharmacies before filling is worth the five minutes it takes.

Compounded bremelanotide from a New York-licensed 503A pharmacy is the steepest discount available without insurance: roughly $140 per month. The legal status of that option is addressed in detail below.

FDA Vyleesi Prescribing Information [1]

Does New York Medicaid Cover Vyleesi?

New York Medicaid does cover Vyleesi, but only after a successful prior authorization (PA) is submitted by the prescribing provider. The PA criteria typically require:

• A confirmed diagnosis of acquired, generalized HSDD in a premenopausal woman
• Documentation that the disorder causes marked distress or interpersonal difficulty
• Confirmation that the low desire is not better explained by a co-existing medical condition, a relationship problem alone, or a medication side effect
• A note ruling out flibanserin (Addyi) as a first-line option, or documenting why it was not appropriate

Managed Long Term Care (MLTC) and Medicaid Managed Care plans in New York follow the same general PA framework, though each plan's formulary tier placement may differ. Prescribers who practice through Federally Qualified Health Centers (FQHCs) or Medicaid-enrolled telehealth platforms in New York can submit the PA on the patient's behalf electronically through the eMedNY portal.

The RECONNECT trials (two 24-week, placebo-controlled studies; combined N = 1,267) demonstrated that bremelanotide 1.75 mg subcutaneous produced statistically significant improvements in the Female Sexual Function Index desire subscale and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score versus placebo, which provides the clinical evidence base that supports Medicaid medical-necessity language. [2]

RECONNECT trial, Obstet Gynecol 2019 [2]

Which Commercial Insurance Plans in New York Cover Vyleesi?

Coverage varies widely by plan type, but the general pattern for 2026 New York commercial insurance is as follows.

Large employer-sponsored PPO/HMO plans (Empire BlueCross, Aetna, UnitedHealthcare) tend to place Vyleesi on Tier 3 or Tier 4 of the formulary, requiring PA and sometimes step therapy through flibanserin first. A Tier 3 copay after PA approval averages $60 to $150 per month for patients who have met their deductible. Before the deductible is met, the patient pays the negotiated plan rate, which is typically $400 to $700 for a 30-day supply at in-network pharmacies.

Individual and small-group plans on the New York State of Health marketplace have inconsistent Vyleesi coverage. As of 2026, fewer than half of the silver-tier plans on NY State of Health list bremelanotide on their standard formulary without an exception process. Patients can request a formulary exception by having their prescriber submit a letter of medical necessity, and New York's external appeal law (NY Insurance Law Article 49) gives enrollees the right to an independent external review if the internal appeal fails.

Medicare does not cover Vyleesi. The drug falls outside Medicare Part D because HSDD is classified as a sexual dysfunction condition excluded from Part D by statute. [3]

NY Insurance Law Article 49 External Appeal overview via CMS [3]

How Does the Palatin Technologies Savings Card Work in New York?

Palatin Technologies (the manufacturer of Vyleesi) offers a co-pay savings program for commercially insured patients. Eligible patients pay as little as $0 per month, with a maximum annual benefit that Palatin has set at $3,600 per calendar year for 2026. The card works at most retail pharmacies in New York that stock Vyleesi, including chains and independent pharmacies that participate in the major switch networks.

Who is NOT eligible: Patients covered by any federal or state government program (Medicare, Medicaid, Tricare, CHIP, Veterans Affairs) cannot use the savings card. New York Medicaid beneficiaries must rely on the PA-based Medicaid coverage pathway described above.

Enrollment is online at the Vyleesi manufacturer website. The prescriber does not need to enroll separately. The patient presents the savings card (or the digital card number) at the pharmacy counter at the time of pickup. If the pharmacy's system rejects the card, the pharmacist can call the adjudication help line printed on the back of the card to resolve the issue in real time.

One practical note: the savings card does not apply to out-of-pocket amounts that accumulate toward a health plan's deductible in most circumstances, so patients on high-deductible plans may want to confirm with their insurer whether card-covered amounts count toward the deductible before assuming the card provides a true zero-cost benefit. [4]

Palatin Technologies Vyleesi patient support information on FDA label page [4]

Is Compounded Bremelanotide Legal in New York?

Compounded bremelanotide from a 503A pharmacy is legal in New York, provided the pharmacy meets all New York State Board of Pharmacy requirements and the prescription is patient-specific. Several conditions must be met for this to be a lawful transaction:

1. The prescription must be written for an individual patient by a licensed prescriber (not a standing order or office-use bulk compounding).
2. The 503A pharmacy must be licensed by New York State and compliant with USP <797> sterile compounding standards, since bremelanotide is a subcutaneous injectable.
3. Bremelanotide is not on the FDA's Category 1 "demonstrably difficult to compound" list as of the publication date of this article, which means compounding for individual patients remains permissible under federal law. [5]
4. The pharmacy cannot compound bremelanotide to be essentially a copy of commercially available Vyleesi without a specific clinical reason documented in the prescription (e.g., patient hypersensitivity to an excipient in the brand formulation).

The New York State Board of Pharmacy exercises strict oversight of 503A sterile compounders. Compounding pharmacies must pass periodic inspections and maintain beyond-use dating documentation for each lot. Patients sourcing compounded bremelanotide should confirm the pharmacy's New York license number on the New York State Office of the Professions license verification portal.

The price differential is real: brand Vyleesi at $1,200 per month versus compounded bremelanotide at approximately $140 per month. That $1,060-per-month gap explains the demand for compounded options. The quality trade-off is that compounded products have not undergone FDA's new drug application (NDA) review for safety, efficacy, or sterility at the manufacturing scale. [5]

FDA 503A compounding regulatory overview [5]

Can You Get Vyleesi via Telehealth in New York?

Yes. Telehealth prescribing of Vyleesi is fully legal in New York as of 2026. The Ryan Haight Online Pharmacy Consumer Protection Act does not restrict bremelanotide prescribing via telehealth because bremelanotide is not a controlled substance (it is not scheduled under the DEA Controlled Substances Act). A prescriber licensed in New York can evaluate a patient via synchronous audio-video telehealth, confirm an HSDD diagnosis using validated tools such as the FSFI (Female Sexual Function Index) and FSDS-DAO, and send a prescription to the patient's preferred pharmacy electronically.

New York's telehealth parity law (NY Public Health Law 2999-cc) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services. An evaluation for HSDD qualifies as a covered outpatient service under most plans, meaning the telehealth consultation itself should carry only a standard copay. [6]

HealthRX clinicians who hold New York licenses can prescribe Vyleesi or, where clinically appropriate, compounded bremelanotide through a fully remote visit. The typical workflow: complete an intake form, join a video consultation, receive an e-prescription, and have the prescription delivered to a local pharmacy or shipped from a compounding pharmacy within 3 to 5 business days.

NY Public Health Law 2999-cc telehealth parity, referenced via CMS [6]

What Does the Clinical Evidence Say About Bremelanotide?

Understanding what you are paying for is part of making an informed decision.

Bremelanotide is a melanocortin receptor agonist that acts centrally, primarily at MC4R receptors, to increase sexual desire. The FDA approved it in June 2019 for HSDD in premenopausal women based on the two RECONNECT trials. [2]

The RECONNECT program enrolled 1,267 premenopausal women with acquired, generalized HSDD across the two studies. At 24 weeks, women randomized to bremelanotide 1.75 mg subcutaneous showed a statistically significant improvement in the FSDS-DAO Item 13 (distress about low sexual desire) versus placebo (P<0.001), and a statistically significant improvement in the FSFI desire domain versus placebo (P<0.001). Responder rates (defined as a clinically meaningful improvement on both co-primary endpoints) were 24.5% for bremelanotide versus 17.0% for placebo. [2]

The most common adverse events reported in RECONNECT were nausea (40.0% bremelanotide vs. 1.3% placebo), flushing (20.4% vs. 0.8%), and injection-site reactions. Transient blood pressure elevation of approximately 2 mmHg systolic occurred within 12 hours of dosing. Bremelanotide is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension. [1]

The 2021 American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on female sexual dysfunction states: "Both flibanserin and bremelanotide are FDA-approved pharmacologic treatments for acquired, generalized HSDD in premenopausal women, and clinicians should discuss the benefits, limitations, and adverse-effect profiles with patients considering either agent." [7]

ACOG Practice Bulletin on female sexual dysfunction [7]

How Vyleesi Compares to Flibanserin (Addyi) on Cost in New York

Flibanserin (Addyi, 100 mg oral tablet nightly) is the only other FDA-approved pharmacologic option for HSDD in premenopausal women. Its 2026 New York cash price is approximately $800 to $900 per month at retail, also with a manufacturer savings card that can reduce cost to $0 for eligible commercially insured patients. Compounded flibanserin is also available from 503A pharmacies at roughly $60 to $90 per month.

The choice between the two drugs is clinical, not purely financial. Bremelanotide is taken as needed (up to one dose per 24 hours), while flibanserin requires nightly dosing with an alcohol contraindication carrying an FDA Risk Evaluation and Mitigation Strategy (REMS) program requirement. Women who prefer not to take a daily pill or who drink alcohol socially often find bremelanotide's as-needed profile more practical, despite the injection route. [8]

FDA Addyi REMS program information [8]

The HealthRX New York Bremelanotide Cost Decision Framework

The following four-step framework helps New York patients choose the most cost-effective path to bremelanotide access:

Step 1: Check your formulary first. Call the member services number on your insurance card and ask whether bremelanotide (NDC prefix 47335) is covered. Get the tier, the PA requirements, and the estimated copay. This call takes ten minutes and prevents a $1,200 surprise at the pharmacy counter.

Step 2: If covered, use the savings card in parallel. Even with insurance, the Palatin savings card can reduce or eliminate your share of the cost up to the $3,600 annual cap. The card and insurance can be stacked in many (but not all) pharmacy systems.

Step 3: If denied or uninsured, file an appeal or consider compounded. New York's external appeal law gives you a legally enforceable right to an independent review of a denial. Your prescriber submits the appeal with the RECONNECT trial data and the ACOG Practice Bulletin as supporting evidence. If the appeal process is too slow for your timeline, a licensed New York 503A compounding pharmacy at ~$140 per month is a lawful interim option.

Step 4: Use a telehealth visit to avoid out-of-pocket consultation costs. A telehealth consultation for HSDD carries only a standard copay under New York's parity law. Starting your Vyleesi journey through telehealth costs no more than any other specialist visit and saves the time of an in-person appointment.

What New York Patients Should Know About Storing and Using Vyleesi

Brand Vyleesi auto-injectors must be stored in the refrigerator (36°F to 46°F / 2°C to 8°C) but may be kept at room temperature up to 77°F (25°C) for up to 30 days. Compounded bremelanotide vials have shorter beyond-use dating, typically 14 to 30 days depending on the compounding pharmacy's validated testing. Patients who travel frequently in New York summers should confirm storage requirements with their pharmacy. [1]

The injection is administered subcutaneously in the abdomen or thigh, 45 minutes before anticipated sexual activity. Women should not inject more than once in 24 hours. The prescribing information advises against using more than eight doses per month, though no monthly dosing ceiling is written into the FDA label as a hard limit. [1]

Nausea is the primary reason patients discontinue bremelanotide. Taking the injection on an empty stomach dramatically increases nausea risk. Clinical prescribers at HealthRX recommend eating a light meal 30 to 60 minutes before injecting and having a small antiemetic (ondansetron 4 mg orally dissolving tablet) on hand for the first two to three doses until individual tolerance is established.

Summary of 2026 Vyleesi Cost Options in New York

| Access pathway | Estimated monthly cost | Key requirement | |---|---|---| | Brand Vyleesi, cash pay | $1,200 | None beyond prescription | | Brand Vyleesi, commercial insurance (post-deductible Tier 3) | $60 to $150 | Prior authorization | | Brand Vyleesi, savings card only (uninsured, eligible) | $0 to $50 | Commercial insurance or savings card enrollment | | New York Medicaid | $0 to minimal copay | Prior authorization via eMedNY | | Compounded bremelanotide, 503A NY pharmacy | ~$140 | Patient-specific Rx, licensed pharmacy |